MedTrace Logo

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

NCT06827080 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-02-14

No results posted yet for this study

Summary

161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.

Conditions

  • Metastatic Castration-resistant Prostate Cancer, MCRPC
  • Cancer

Interventions

DRUG

30 mCi NYMO32

The initial dose is set at 30 mCi.

DRUG

50 mCi NYMO32

The dose will be escalated to 50 mCi.

DRUG

80 mCi NYMO32

The dose will be escalated to 80 mCi.

DRUG

130 mCi NYMO32

The dose will be escalated to 130 mCi.

DRUG

200 mCi NYMO32

The maximum dose is set at 200 mCi.

Sponsors & Collaborators

  • Zhengguo Chen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-11
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827080 on ClinicalTrials.gov